NCT01738139View on ClinicalTrials.gov

Ipilimumab and Imatinib Mesylate in Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 19, 2013

Primary Completion Date

December 13, 2022

Study Completion Date

December 13, 2023

Conditions

Advanced Malignant Solid NeoplasmC-KIT Tyrosine Kinase Protein OverexpressionClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Gastrointestinal Stromal TumorMetastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8Unresectable MelanomaUnresectable Solid Neoplasm

Interventions

DRUG

Imatinib Mesylate

Given PO

BIOLOGICAL

Ipilimumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01738139 - Ipilimumab and Imatinib Mesylate in Advanced Cancer | Biotech Hunter | Biotech Hunter